RECQL1 as a potential therapeutic target for PARP inhibitor-resistant ovarian cancer
Open Access
- 30 October 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-11
Abstract
Overcoming resistance to poly (ADP-ribose) polymerase (PARP) inhibitors is an urgent challenge for ovarian cancer treatment. Here, we investigated RECQL1, a RecQ helicase involved in homologous recombination repair, as a potential target for overcoming PARP inhibitor resistance in this disease. Patients with platinum-sensitive recurrent ovarian cancer treated with the PARP inhibitor olaparib between March 2018 and December 2021 were included. Immunohistochemistry assays were conducted to assess RECQL1 protein expression patterns in surgically resected ovarian cancer tissues. The effect of RECQL1 knockdown on olaparib resistance was evaluated in vitro using ovarian cancer cells transfected with an anti-RECQL1 siRNA. Among 44 patients, those with no response to olaparib had significantly higher RECQL1 expression levels compared with responders (P = 0.020). Kaplan–Meier curves showed significantly shorter overall survival in the high RECQL1 expression group than in the low expression group (median, 26.0 months vs. not reached; P = 0.027). Multivariate analysis revealed high RECQL1 expression to be a significant prognostic factor for shorter overall survival (P = 0.036). RECQL1 knockdown significantly enhanced the sensitivity to olaparib in two ovarian cancer cell lines. Overall, RECQL1 plays a critical role in PARP inhibitor resistance and is a promising therapeutic target to improve ovarian cancer patient outcomes.Keywords
Funding Information
- Japan Society for the Promotion of Science (22K09552)
This publication has 45 references indexed in Scilit:
- Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancerCancer Medicine, 2024
- PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathwayBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumorNeoplasia, 2020
- Therapeutic applications of PARP inhibitors in ovarian cancerBiomedicine & Pharmacotherapy, 2020
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated CellsTrends in Cell Biology, 2019
- Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibitionCancer Treatment Reviews, 2018
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- A brief review of the management of platinum-resistant–platinum-refractory ovarian cancerMedical Oncology, 2017
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancerGynecologic Oncology, 2014
- Evolution of platinum resistance in high-grade serous ovarian cancerThe Lancet Oncology, 2011